As temperatures drop sharply across Corsica this week, public health authorities are calling for vigilance while influenza activity remains at a baseline level, three weeks after the launch of the vaccination campaign.
Data from Santé publique France indicates that viral circulation remains low, but local health officials warn that it is too early to assess the final impact of the current vaccination drive.
The regional health agency ARS notes that the campaign began three weeks ago and that it is “too early to draw up an assessment of the season, as well as that of the vaccination campaign.”
Beyond vaccination, the ARS stresses “the importance of barrier gestures to slow the circulation of respiratory viruses,” such as hand washing, airing rooms and mask-wearing when symptomatic.
Essential Guidance for Seasonal Protection
- Co-administration: Vaccination against both influenza and Covid-19 is safe and recommended; injections can be performed on the same day in different arms or scheduled days apart.
- Access: Eligible individuals receive a voucher from the national health insurance, allowing for free influenza vaccines at local pharmacies, which can be administered by physicians, nurses, pharmacists, or midwives.
Regional Vaccination Rates Trail National Averages
Public health data reveals a significant gap between current vaccination rates in Corsica and the 75% target established by the World Health Organization. During the 2025-2026 season, only 49% of Corsican residents aged 65 and older received the influenza vaccine. Among those under 65 with underlying medical risk factors, the uptake was notably lower, at just 21%. These figures sit eight percentage points below the national average for mainland France, highlighting a pressing need for improved patient outreach.
To address this, Swiss authorities have designated two national vaccination weeks—beginning November 2 and November 23, 2026—to improve accessibility.
The Federal Office of Public Health (OFSP) states that vaccination remains a personal choice and aims to allow informed decisions, with information available on vacciner-suisse.ch. Influenza recommendations are unchanged, while Covid-19 and RSV guidance have been slightly adapted.
Clinical Considerations for Respiratory Virus Prevention
The current clinical approach prioritizes high-risk groups, including pregnant women, the elderly, and those with chronic conditions. While the influenza and Covid-19 vaccines are primary tools, other immunizations, such as those for pneumococcal disease and the Respiratory Syncytial Virus (VRS), are also being integrated into seasonal protocols. In the Canton of Vaud, authorities recommend the VRS vaccine for those over 75 and individuals over 60 with specific risk factors, noting that while the vaccine is not reimbursed by mandatory insurance, it protects against complications.
The Aviq calls vaccination “one of the most effective means to reduce the risk of severe forms of certain respiratory infections.” While flu and Covid-19 vaccines can be administered in pharmacies, the pneumococcal vaccine requires a general practitioner, and the RSV vaccine is recommended for pregnant women expecting in autumn or winter to protect against bronchiolitis.
| Vaccine Category | Primary Target Population | Administration Note |
|---|---|---|
| Influenza | 65+, Pregnant, Chronic illness | Free with health insurance voucher |
| Covid-19 | General population/At-risk | Entirely free of charge |
| VRS | 75+, 60+ with risk factors, Pregnant | Physician-led administration |
Tailor Vaccination Decisions to Individual Health Histories
Vaccination is a clinical decision that should be tailored to individual health histories.
While the current epidemiological situation in Corsica shows that Covid-19 is present but has a limited impact on emergency department admissions, the potential for transmission during the winter months remains a context for vigilance.
